Extracts from Syngene Annual Report
CRO,CMO Business
Global CRO Market to grow at CAGR of 7.6% 2019 to 2025 to reach $61 billion
Pharma & biopharmaceutical companies - primary users of CRO services
CRO,CMO Business
Global CRO Market to grow at CAGR of 7.6% 2019 to 2025 to reach $61 billion
Pharma & biopharmaceutical companies - primary users of CRO services
Offlate medical device companies, consumer products,cosmetics, specialty & agrochemicals are also employing the services of CROs
CROs are alts to inhouse R&D, help pharma & biopharma to cut R&D costs manage regulatory requirements, increase speed to market of life saving drugs
CROs are alts to inhouse R&D, help pharma & biopharma to cut R&D costs manage regulatory requirements, increase speed to market of life saving drugs
CRO market
A)Drug discovery - market expected to grow from $3.9bn in 2017 to $6.8bn in 2025 ,CAGR of 7.37%
B)Pre clinical - market expected to grow from $3.5bn in 2017 to $ 6.6bn in 2025 ,CAGR of 8.31%
C) Clinical - market to grow from $25.5bn in 2017 to $41.2bn in 2025
A)Drug discovery - market expected to grow from $3.9bn in 2017 to $6.8bn in 2025 ,CAGR of 7.37%
B)Pre clinical - market expected to grow from $3.5bn in 2017 to $ 6.6bn in 2025 ,CAGR of 8.31%
C) Clinical - market to grow from $25.5bn in 2017 to $41.2bn in 2025
CAGR of 6.6 %
Preclinical to be the fastest growing segment ,CAGR of 8.31% ,development of targeted therapies in cancer & other disease made possible due to increased information available on the human genome,higher number of product approvals by USFDA
Preclinical to be the fastest growing segment ,CAGR of 8.31% ,development of targeted therapies in cancer & other disease made possible due to increased information available on the human genome,higher number of product approvals by USFDA
Oncology - largest share of revenue to CRO market, CAGR of 7.5% from 2018 -25,due to growing incidence of cancer
Pharma companies increasingly using CMO services, to increase capacity, gain access 2 sophisticated services,mitigate risks associated with failure of pipeline drugs
Pharma companies increasingly using CMO services, to increase capacity, gain access 2 sophisticated services,mitigate risks associated with failure of pipeline drugs
Decrease costs required for setting up new manufacturing facilities, decrease R&D costs
CMO's are developing capabilities of both APIs and dose manufacturing
Dose CMO contract revenue 2017 - $ 20.1 bn ,2018 - $ 21.4bn ,growth of 6.1%,highest y-o-y growth since 2012
CMO's are developing capabilities of both APIs and dose manufacturing
Dose CMO contract revenue 2017 - $ 20.1 bn ,2018 - $ 21.4bn ,growth of 6.1%,highest y-o-y growth since 2012
Biologics market
2018 - only 2 of top 10 selling drugs were small molecules, biologics drove 80% sales.By 2020 a number of biologics will lose patents, biosimilars will take their place
2018 - only 2 of top 10 selling drugs were small molecules, biologics drove 80% sales.By 2020 a number of biologics will lose patents, biosimilars will take their place
According to Grand view research global CRO & CMO market size to reach $37.8 billion by 2025 ,7.7% CAGR
@unseenvalue @AdityaKhemka5 @punitbansal14 @SyngeneIntl @kiranshaw @Bioconlimited #CDMO #biosimilars
Unroll
@threadreaderapp
@unseenvalue @AdityaKhemka5 @punitbansal14 @SyngeneIntl @kiranshaw @Bioconlimited #CDMO #biosimilars
Unroll
@threadreaderapp
